SMA Targeted Magnetic Stimulation Against Auditory Verbal Hallucinations
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Auditory Hallucination
- Sponsor
- Uppsala University
- Enrollment
- 46
- Locations
- 1
- Primary Endpoint
- Amplitude on EEG in speech-listen task
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
Auditory verbal hallucinations (AVH) are prevalent among patients with psychiatric disorders. Not only being highly stressful and functionally impairing, AVH often persist despite treatment. Recent attempts to treat AVH with add-on repetitive transcranial magnetic stimulation (rTMS) when targeting the temporoparietal junction (TPJ), a language node in the brain, has gained limited success. The aim of this investigation is to reduce AVH with rTMS using continous theta-burst stimulation over a novel target, the supplementary motor area (SMA), in participants with frequent AVH, while also assessing potential neurophysiological mechanisms underlying the symptom.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria for the AVH group:
- •Reported AVH with a minimum frequency of at least daily occurrence, with onset more than one month ago
- •Stable psychopharmacological treatment past month
- •Inclusion criteria for the non-AVH control group
- •Reporting no occurrences of AVH for the past year
- •Stable psychopharmacological treatment past month
- •Inclusion criteria for the healthy control group
- •No life-time occurrence of AVH
- •No history of psychiatric disorders as assessed with a Mini-International Neuropsychiatric Interview (M.I.N.I.)
Exclusion Criteria
- •Ferromagnetic or electromagnetic implants that may pose a risk during magnetic resonance imaging (MRI) and/or cTBS
- •A history of epilepsy
- •Pregnancy
- •Current substance use disorder or a history of alcohol use disorder as assessed with Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT), urine samples with test for illicit drugs and Phosphatidylethanol (PEth)
- •Daily benzodiazepine use
- •Factors that make the participant unlikely to be able to complete the study
Outcomes
Primary Outcomes
Amplitude on EEG in speech-listen task
Time Frame: 5-30 minutes after intervention
Neurophysiological outcome of the blinded cross-over phase
Change on The Psychotic Symptom Rating Scales (PSYRATS)
Time Frame: 1 day after completion of open treatment phase
Auditory Verbal Hallucination symptom interview, total score
Secondary Outcomes
- Double step saccade-task(20-60 minutes after intervention)
- Finger tapping test(5-30 minutes after intervention)
- Brief Psychiatric Rating Scale (BPRS)(1 day after completion of open treatment phase)
- Resting state functional magnetic resonance imaging (rsfMRI)(1 day after completion of open treatment phase)
- Magnetic resonance spectroscopy (MRS) over the SMA quantifying glutamate and gamma-aminobutyric acid (GABA) and other metabolites(1 day after completion of open treatment phase)
- App recorded ratings of auditory verbal hallucinations (AVH)(From first day of open treatment phase, and through one week after completion of treatment)